pocketful logo light
pocketful logo light
Indoco Remedies Ltd logo

Indoco Remedies Ltd

NSE: INDOCO BSE: 532612

209.60

(1.00%)

Sat, 30 May 2026, 10:52 am

Indoco Remedies Share Price Live Chart

1 Day

(1.00%)

No Result Found

Summary

  • Market Cap

    1935.15

  • Net Profit

    -77.95

  • P/B

    2.11

  • Sector P/E

    34.30

  • P/E

    0

  • EV/EBITDA

    29.60

  • Debt/Equity (Industry)

    0.24

  • Interest Cover (Industry)

    9.79

  • ROCE (Industry)

    14.04

  • RONW (Industry)

    13.17

  • ROE

    -7.31

  • ROCE

    -0.42

  • Debt/Equity

    0.78

  • EPS (TTM)

    0

  • Dividend Yield

    0.10

  • Book Value

    101.76

  • Interest Cover

    -0.12

Analysis

all

thumbs up icon

Pros

  • Indoco Remedies's earnings are expected to grow significantly at over 20% yearly.
  • Indoco Remedies's earnings growth is expected to exceed the India market average.
  • Indoco Remedies's earnings growth is expected to exceed the low risk savings rate of 7.2%.
  • Indoco Remedies's earnings are expected to exceed the low risk growth rate next year.
  • Indoco Remedies's net income is expected to increase by more than 50% in 2 years time.
thumbs up icon

Cons

  • Indoco Remedies is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
  • No need to calculate the sustainability of Indoco Remedies's dividends as it is not paying a notable one for India.
  • Indoco Remedies is not paying a notable dividend for India, therefore no need to check if the payments are stable.
  • Indoco Remedies's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Indoco Remedies's dividend is below the markets top 25% of dividend payers in India (3.08%).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters58.8658.9058.9058.9058.90
FII0.941.101.251.221.24
DII18.1518.1518.1618.9618.75
Public22.0421.8521.6920.9221.11
Government00000

Read More

Technical Analysis

RSI

49.68

MACD

-2.24

50 DMA

205.31

200 DMA

240.61

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic322.13261.89235.69201.65175.45141.4181.17
Fibonacci261.89238.88224.66201.65178.64164.42141.41
Camarilla226.06220.53215.01201.65203.97198.45192.92

Pivots Level: Classic

R3

+120.48

322.13

R2

+60.24

261.89

R1

+34.04

235.69

201.65
201.65
Pivot Point
LTP: 209.66

S1

-26.20

175.45

S2

-60.24

141.41

S3

-120.48

81.17

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    206.88

  • 20-EMA

    209.94

  • 30-EMA

    210.04

  • 50-EMA

    209.73

  • 100-EMA

    215.75

  • 200-EMA

    233.02

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
07 May 2026board-meetingsAccounts, Final Dividend
03 Feb 2026board-meetingsQuarterly Results
06 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
14 Aug 2025agm
04 Aug 2025dividendFinal Dividend - Rs. - 0.204 Sept 2025
22 May 2025dividend₹0.20 Dividend /Share04 Sept 2025
30 Aug 2024agm
19 Aug 2024dividendAnnual General Meeting/Dividend - Rs 1.50 Per Share20 Sept 2024
16 May 2024dividend₹1.50 Dividend /Share19 Sept 2024
28 Aug 2023agm

Read More

Peer Comparison

Indoco Remedies Ltd logo

Indoco Remedies Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Read More

Indoco Remedies Ltd About

Indoco Remedies is engaged in the manufacturing and marketing of Formulations and Active Pharmaceutical Ingredients. The Company caters to both Domestic and International markets.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1947

Headquarters

CEO

Suresh G Kare

Employees

Contact

Website icon

Website

http://www.indoco.com

Email icon

Email

compliance.officer@indoco.com

Phone icon

Phone

91-022-26541851-55

Location icon

Location

Indoco House 166 C S T Road, Santacruz (East) Kalina, Mumbai, Maharashtra, 400098

Read More

Indoco Remedies Ltd Company History

YearHistory
2020
  • Indoco wins major tenders in Germany for Allopurinol Tablets
  • Indoco receives USFDA approval for Apixaban Tablets 2.5 mg & 5 mg
  • Indoco awarded with the IDMA Formulations Best Patent Award 2018-19 for 2 formulation patents Diclofenac & Quetiapine
  • Indoco receives USFDA approval for Succinylcholine Chloride Injection USP
  • Indoco receives USFDA approval for Olanzapine Tablets
2021
  • Indoco announces the launch of Brinzolamide Ophthalmic Suspension 1% in the US market by Teva Pharmaceuticals
2022
  • Indoco Remedies to acquire stake in Kanakal Wind Energy.
  • Indoco Remedies receives USFDA approval for Lacosamide Injection USP.
  • Indoco Remedies receives USFDA approval for Lacosamide Tablets.
2023
  • Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin Tablets.
  • Indoco acquires 85 % equity stake in US based FPP Holding Company, LLC.
  • Indoco receives EIR for its manufacturing facility in Goa (Plant I).
2024
  • Indoco enters into a strategic distribution partnership with Clarity Pharma, UK.
  • Indoco Remedies receives final ANDA approval from USFDA for Varenicline Tablets, 0.5 mg and 1 mg
  • Indoco Remedies receives final ANDA approval from USFDA for Pregabalin capsules.
  • Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets.
  • USFDA successfully completes inspection at Indoco's API Kilo Lab manufacturing facility and IAS division without any observations.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
ICICI PRUDENTIAL MUTUAL FUNDbulkBuy68354419827 May 2026
ICICI PRUDENTIAL MUTUAL FUNDbulkBuy67445819827 May 2026
XTX MARKETS LLPbulkBuy478901507.9412 Aug 2021
XTX MARKETS LLPbulkSell481713508.5112 Aug 2021
DOVETAIL INDIA FUND CLASS 6 SHARESbulkBuy500000265.3102 Dec 2020
OHM JUNIPER LONGTERM FUND LTDbulkSell500000265.3102 Dec 2020
DSP AIF PHARMA FUNDbulkSell127643414010 Oct 2019
DSP AIF PHARMA FUNDblockSell127643414010 Oct 2019
DSP MUTUAL FUNDbulkBuy127643414010 Oct 2019
DSP MUTUAL FUNDblockBuy127643414010 Oct 2019

Read More

Indoco Remedies Ltd News

Indoco Remedies Transfers Ophthalmic Division to Sunways

Indoco Remedies completes transfer of its ophthalmic business to Sunways (India) Private Limited on a slump sale basis, effective May 18, 2026.

18 May 2026

companies

Indoco Remedies Director Dr. Anand Nadkarni Passes Away

Indoco Remedies reports the demise of Dr. Anand Nadkarni, Non-Executive Director (DIN: 06881461), on 15th May, 2026, under SEBI Regulation 30 disclosure norms.

15 May 2026

companies

Indoco Remedies Facility Earns EU GMP Certification

Indoco Remedies' facility has received EU GMP Certification from the Malta Medicines Authority for meeting Good Manufacturing Standards.

14 May 2026

companies

Indoco Remedies FY26 Results Published in Newspapers

Indoco Remedies published its audited Q4 & FY26 financial results in Business Standard and Mumbai Lakshadeep on May 8, 2026, per SEBI Regulation 30 & 47.

09 May 2026

companies

Indoco Remedies FY26 Results Published in Newspapers

Indoco Remedies published its audited Q4 & FY26 financial results in Business Standard and Mumbai Lakshadeep on May 8, 2026, per SEBI Regulation 30 & 47.

08 May 2026

companies

Read More